Trial record 1 of 617 for:    "Crohns disease"
Previous Study | Return to List | Next Study

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs (TOSCA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01387594
First received: June 30, 2011
Last updated: August 12, 2014
Last verified: August 2014
  Purpose

Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.


Condition Intervention Phase
Crohn's Disease
Ileitis
Ileo-colonic and Colonic Crohn's Disease
Granulomatous Colitis
Regional Enteritis
Ulcerative Colitis
Procedure: lumbar puncture
Drug: lumbar puncture
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Multi Center, Phase 1, Open Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Are Anti- TNF Inadequate Responders (TOSCA)

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percent change from baseline (pre treatment) in absolute lymphocyte count in CSF in subjects with CD or UC after receiving 3 monthly doses of PF-00547659 [ Time Frame: Week 9-11 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Frequency of on treatment adverse events, withdrawal due to adverse events, and serious adverse events (SAEs) will be reported [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]
  • Proportion of subjects developing anti-drug antibodies (ADA) to PF-00547659 [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]
  • Frequency of injection site reactions and other hypersensitivity reactions [ Time Frame: Week 36 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: May 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Interventions prior to treatment. Control arm
Procedure: lumbar puncture
2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
Experimental: Cohort 2
Interventions prior to and after 3 monthly injections
Drug: lumbar puncture
1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • males and females >=18 and =<75 years
  • For CD subjects: hsCRP > 5 mg/L and Harvey-Bradshaw Index > 8 OR when HBI cannot be determined (ie if stoma is present) or hsCRP < 5mg/L then: active lesions on colonoscopy or flexible sigmoidoscopy or active Crohn's disease on CT or MR enterography
  • For UC subjects: diagnosis of UC > 3 months; must have endoscopy to confirm active disease during screening; total mayo score of 6 to 12 points and moderate to severe disease on endoscopy

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • TB or active enteric infections
  • Entero vesicular fistulae
  • Prior use of natalizumab or vedolizumab
  • Right or left heart failure including symptomatic diastolic dysfunction or unexplained elevation of troponin I (>0.05 ng/mL)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01387594

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
Austria
Pfizer Investigational Site Recruiting
Wien, Austria, 1090
Belgium
Pfizer Investigational Site Recruiting
Brussels, Belgium, B-1070
Pfizer Investigational Site Recruiting
Leuven, Belgium, 3000
France
Pfizer Investigational Site Recruiting
Lille, France, 59037
Pfizer Investigational Site Recruiting
Lille Cedex, France, 59037
Pfizer Investigational Site Recruiting
Paris, France, 75010
Germany
Pfizer Investigational Site Recruiting
Berlin, Germany, 13353
Pfizer Investigational Site Not yet recruiting
Kiel, Germany, 24105
Netherlands
Pfizer Investigational Site Recruiting
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01387594     History of Changes
Other Study ID Numbers: A7281008
Study First Received: June 30, 2011
Last Updated: August 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Crohn's disease lumbar puncture anti-MAdCAM monoclonal antibody PF-00547659 Ulcerative Colitis

Additional relevant MeSH terms:
Crohn Disease
Ulcer
Colitis, Ulcerative
Colitis
Pathologic Processes
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Inflammatory Bowel Diseases
Colonic Diseases
Intestinal Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014